Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Approvals Near For Four New Drugs, One New Indication

 
• By Mandy Jackson
Office building at Lilly's Indianapolis HQ
Lilly's donanemab setback still could result in a win with positive Phase III data in Q2 • Source: Shutterstock

More from New Products

More from Scrip